BMY-28121, a new antitumor antibiotic

Details BMY-28121, a new antitumor antibiotic BMY-28121, a new antitumor antibiotic

1985-02-25

1987-07-28

Bond, Robert T.

Electric lamp and discharge devices: consumable electrodes

With economizer

540496, 435119, A61K 3155, C07D48704

Patent

active

046832300

ABSTRACT:
A new antitumor antibiotic designated herein as BMY-28121 is produced by fermentation of Streptomyces albus strain K731-113 (ATCC 39897). BMY-28121, which may be recovered from the fermentation broth in either its natural free hydroxy form (BMY-28121A) or methyl ether form (BMY-28121B), inhibits gram-positive bacteria and anaerobes and inhibits the growth of mammalian tumors such as P-388 leukemia, L-1210 leukemia and B16 melanoma.

REFERENCES:
J. Am. Chem. Soc. 87: 5791-5793, (1965).
J. Antibiotics, 33(6): 665-667, (1980).
J. Antibiotics 27(11): 886-873 (1974).
J. Antibiotics 25(11): 668-673 (1972).
J. Antibiotics 25: 437-444 (1972).
J. Antibiotics 29(1): 93-96 (1976).
J. Antibiotics 30: 340-343 (1977).
J. Antibiotics 37: 191-199 (1984).

Affiliated with

Also associated with

Rating

BMY-28121, a new antitumor antibiotic does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BMY-28121, a new antitumor antibiotic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BMY-28121, a new antitumor antibiotic will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2035025